Tumor-targeted responsive nanoparticle-based systems for magnetic resonance imaging and therapy

Pharmaceutical Research

Volumn 31, Issue 12, 2014, Pages 3487-3502

  Savla, Ronak ^a   Garbuzenko, Olga B ^a   Chen, Suzie ^a,b,c   Rodriguez Rodriguez, Lorna ^b,d   Minko, Tamara ^a,b,c  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

LHRH targeting peptide; manganese oxide nanoparticles; MMP2 cleavable peptide; nanostructured lipid carriers; vemurafenib

Indexed keywords

ANTINEOPLASTIC AGENT; BIOMATERIAL; CONTRAST MEDIUM; DRUG CARRIER; INDOLE DERIVATIVE; MANGANESE DERIVATIVE; MANGANESE OXIDE; MONOCLONAL ANTIBODY; NANOPARTICLE; OXIDE; SULFONAMIDE; VEMURAFENIB;

ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FEMALE; HUMAN; LUNG NEOPLASMS; MALE; MELANOMA; MOUSE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARIAN NEOPLASMS; PROCEDURES; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; CELL SURVIVAL; CONTRAST MEDIA; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INDOLES; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MANGANESE COMPOUNDS; MELANOMA; MICE; NANOPARTICLES; OVARIAN NEOPLASMS; OXIDES; SULFONAMIDES; TISSUE DISTRIBUTION;

EID: 84936059670     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1436-x     Document Type: Article

References (58)

1. Fang C, Zhang M. Nanoparticle-based theragnostics: integrating diagnostic and therapeutic potentials in nanomedicine. J Control Release. 2010;146:2-5.
2. Chen Y, Yin Q, Ji X, Zhang S, Chen H, Zheng Y, et al. Manganese oxide-based multifunctionalized mesoporous silica nanoparticles for pH-responsive MRI, ultrasonography and circumvention of MDR in cancer cells. Biomaterials. 2012;33:7126-37.
3. Lee YC, Chen DY, Dodd SJ, Bouraoud N, Koretsky AP, Krishnan KM. The use of silica coated MnO nanoparticles to control MRI relaxivity in response to specific physiological changes. Biomaterials. 2012;33:3560-7.
4. Yang H, Zhuang YM, Hu H, Du XX, Zhang CX, Shi XY, et al. Silica-coated manganese oxide nanoparticles as a platform for targeted magnetic resonance and fluorescence imaging of cancer cells. Adv Funct Mater. 2010;20:1733-41.
5. Huang WY, Davis JJ. Multimodality and nanoparticles in medical imaging. Dalton Trans. 2011;40:6087-103.
6. Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomed. 2011;6:715-28.
7. Frangioni JV. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol. 2003;7:626-34.
8. Ntziachristos V, Ripoll J, Weissleder R. Would near-infrared fluorescence signals propagate through large human organs for clinical studies? Errata Opt Lett. 2002;27:1652.
9. Chandna P, Khandare JJ, Ber E, Rodriguez-Rodriguez L, Minko T. Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers. Pharm Res. 2010;27:2296-306.
10. Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, Gunaseelan S, et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci U S A. 2005;102:12962-7.
11. Khandare JJ, Chandna P, Wang Y, Pozharov VP, Minko T. Novel polymeric prodrug with multivalent components for cancer therapy. J Pharmacol Exp Ther. 2006;317:929-37.
12. Minko T, Patil ML, Zhang M, Khandare JJ, Saad M, Chandna P, et al. LHRH-targeted nanoparticles for cancer therapeutics. Methods Mol Biol. 2010;624:281-94.
13. Shah V, Taratula O, Garbuzenko OB, Taratula OR, Rodriguez-Rodriguez L, Minko T. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of sirna and anticancer drug. Clin Cancer Res. 2013;19:6193-204.
14. Taratula O, Garbuzenko OB, Kirkpatrick P, Pandya I, Savla R, Pozharov VP, et al. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Release. 2009;140:284-93.
15. Taratula O, Kuzmov A, Shah M, Garbuzenko OB, Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release. 2013;171:349-57.
16. Zhang M, Garbuzenko OB, Reuhl KR, Rodriguez-Rodriguez L, Minko T. Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases. Nanomed. 2012;7:185-97.
17. Saad M, Garbuzenko OB, Ber E, Chandna P, Khandare JJ, Pozharov VP, et al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging? J Control Release. 2008;130:107-14.
18. Yin M, O'Brien S. Synthesis of monodisperse nanocrystals of manganese oxides. J Am Chem Soc. 2003;125:10180-1.
19. Bae KH, Lee K, Kim C, Park TG. Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging. Biomaterials. 2011;32:176-84.
20. Bennewitz MF, Lobo TL, Nkansah MK, Ulas G, Brudvig GW, Shapiro EM. Biocompatible and pH-Sensitive PLGA Encapsulated MnO Nanocrystals for Molecular and Cellular MRI. ACS Nano. 2011;5:3438-46.
21. Howell M, Mallela J, Wang C, Ravi S, Dixit S, Garapati U, et al. Manganese-loaded lipid-micellar theranostics for simultaneous drug and gene delivery to lungs. J Control Release. 2013;167:210-8.
22. Na HB, Lee JH, An KJ, Park YI, Park M, Lee IS, et al. Development of a T-1 contrast agent for magnetic resonance imaging using MnO nanoparticles. Angew Chem Int Ed. 2007;46:5397-401.
23. Pan D, Caruthers SD, Senpan A, Schmieder AH, Wickline SA, Lanza GM. Revisiting an old friend: manganese-based MRI contrast agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;3:162-73.
24. Yu T, Moon J, Park J, Park YI, Bin Na H, Kim BH, et al. Various-Shaped Uniform Mn3O4 Nanocrystals Synthesized at low temperature in air atmosphere. Chem Mater. 2009;21:2272-9.
25. Minko T, Kopeckova P, Kopecek J. Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J Control Rel Off J Control Rel Soc. 1999;59:133-48.
26. Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2004;15:517-25.
27. Matsumura Y. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv Drug Delivery Rev. 2008;60:899-914.
28. Batist G, Gelmon KA, Chi KN, Miller Jr WH, Chia SK, Mayer LD, et al. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res. 2009;15:692-700.
29. Seymour LW, Ferry DR, Kerr DJ, Rea D, Whitlock M, Poyner R, et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol. 2009;34:1629-36.
30. Valle JW, Armstrong A, Newman C, Alakhov V, Pietrzynski G, Brewer J, et al. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest New Drugs. 2011;29:1029-37.
31. Patil ML, Zhang M, Minko T. Multifunctional triblock Nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular siRNA delivery and gene silencing. ACS Nano. 2011;5:1877-87.
32. Huang ZR, Hua SC, Yang YL, Fang JY. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol Sin. 2008;29:1094-102.
33. Li X, Nie SF, Kong J, Li N, Ju CY, Pan WS. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm. 2008;363:177-82.
34. Das S, Ng WK, Tan RB. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci. 2012;47:139-51.
35. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Delivery Rev. 2002;54 Suppl 1:S131-55.
36. Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm Off J Arbeitsgemeinschaft fur Pharmazeutisc. 2008;70:633-40.
37. Saupe A, Gordon KC, Rades T. Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy. Int J Pharm. 2006;314:56-62.
38. Zhu L, Kate P, Torchilin VP. Matrix Metalloprotease 2-Responsive Multifunctional Liposomal Nanocarrier for Enhanced Tumor Targeting. ACS Nano. 2012;6:3491-8.
39. Serrat FB. 3,3,5,5 -Tetramethylbenzidine for the colorimetric determination of manganese in water. Mikrochim Acta. 1998;129:77-80.
40. Zheng Y, Thomas-Schoemann A, Sakji L, Boudou-Rouquette P, Dupin N, Mortier L, et al. An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients. J Chromatogr B. 2013;928:93-7.
41. Savla R, Taratula O, Garbuzenko O, Minko T. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J Control Release. 2011;153:16-22.
42. Garbuzenko OB, Saad M, Pozharov VP, Reuhl KR, Mainelis G, Minko T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci U S A. 2010;107:10737-42.
43. Taratula O, Garbuzenko OB, Chen AM, Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target. 2011;19:900-14.
44. Alb M, Sie C, Adam C, Chen S, Becker JC, Schrama D. Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma. Cancer Immunol Immunother. 2012;61:2239-49.
45. Schiffner S, Chen S, Becker JC, Bosserhoff AK. Highly pigmented Tg(Grm1) mouse melanoma develops non-pigmented melanoma cells in distant metastases. Exp Dermatol. 2012;21:786-8.
46. Singh A, Sahoo SK. Magnetic nanoparticles: a novel platform for cancer theranostics. Drug Discov Today. 2013;19:474-81.
47. Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol. 2004;4:469-78.
48. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161-74.
49. Park J, Kang EA, Bae CJ, Park JG, Noh HJ, Kim JY, et al. Synthesis, characterization, and magnetic properties of uniform-sized MnO nanospheres and nanorods. J Phys Chem B. 2004;108:13594-8.
50. Tong S, Hou SJ, Ren BB, Zheng ZL, Bao G. Self-assembly of Phospholipid-PEG coating on nanoparticles through dual solvent exchange. Nano Lett. 2011;11:3720-6.
51. Garbuzenko O, Barenholz Y, Priev A. Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chem Phys Lipids. 2005;135:117-29.
52. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26:3995-4021.
53. Uner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie. 2006;61:375-86.
54. Bocca C, Caputo O, Cavalli RB, Gabriel L, Miglietta A, Gasco MR. Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles. Int J Pharm. 1998;175:185-93.
55. Gallo J, Long NJ, Aboagye EO. Magnetic nanoparticles as contrast agents in the diagnosis and treatment of cancer. Chem Soc Rev. 2013;42:7816-33.
56. Rosen JE, Chan L, Shieh DB, Gu FX. Iron oxide nanoparticles for targeted cancer imaging and diagnostics. Nanomed-Nanotechnol. 2012;8:275-90.
57. Shah V, Taratula O, Garbuzenko OB, Patil ML, Savla R, Zhang M, et al. Genotoxicity of different nanocarriers: possible modifications for the delivery of nucleic acids. Curr Drug Discov Technol. 2013;10:8-15.
58. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF and BRAF mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15:323-32.